Clinical trials: Drug Use Disorder
Drug Use Disorders
Targeting Self-regulatory Deficits Through Cognitive Remediation Intervention
We are proposing a small randomized clinical trial in which 100 substance users will complete the existing Psychotherapy Development Center (PDC) pretreatment assessment battery as well as a novel battery of assays to evaluate…
- Trial name
- NCT03373240
- Testing
- TAU plus Cognitive Remediation Program, TAU plus Control Tasks
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Yale University
Opioid-Related Disorders
Trial of Adherence App for Buprenorphine Treatment (TAAB) Study
The purpose of this study is to pilot test a smartphone application that allows video-based directly observed therapy for participants receiving buprenorphine treatment for opioid use disorder in office-based settings.
- Trial name
- NCT03779997
- Testing
- Video-based DOT Application
- Where
- 2 sites in United States
- Volunteers
- 78 people
- Sponsor
- University of Washington
Skin Cancer
Evaluation of Adherence to Topical Agents: Applying Communication Technology to Improve Sunscreen Use
The purpose of this study is to determine if using an electronic reminder improves adherence to sunscreen use. The specific study aims are as follows: 1.
- Trial name
- NCT00535769
- Testing
- Electronic + no text message, Electronic monitor + text messages
- Where
- 2 sites in United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Asthma
Long Term Special Drug Use Investigation of Mepolizumab
This study is a special drug use investigation program of NUCALA (a brand name for Mepolizumab) administered subcutaneously (SC).
- Trial name
- NCT03028480
- Testing
- NUCALA Injection
- Volunteers
- 1,061 people
- Sponsor
- GlaxoSmithKline
Smoking Cessation
Study To Evaluate Cardiac Assessments Following Different Treatments Of Smoking Cessation Medications In Subjects With And Without Psychiatric Disorders.
Non-treatment extension to study A3051123, aimed at collecting data on cardiovascular safety for all participants in the A3051123 trial for an additional 28 weeks, allowing for a total of 52 weeks of cardiovascular safety data…
- Trial name
- CATS (NCT01574703)
- Testing
- varenicline tartrate, bupropion hydrochloride, Nicotine Replacement Therapy Patch
- Where
- 134 sites in United States, Argentina and 14 more
- Volunteers
- 4,595 people, healthy volunteers welcome
- Sponsor
- Pfizer
Type 2 Diabetes Mellitus
A Study to Assess the Safety, Tolerability and Glucose-Lowering Efficacy of MK-0893 in Participants With Type 2 Diabetes Mellitus (MK-0893-005)
This study will assess the safety, tolerability and glucose-lowering efficacy of MK-0893 in participants with type 2 diabetes mellitus.
- Trial name
- NCT02004886
- Testing
- MK-0893, Metformin
- Volunteers
- 74 people
- Sponsor
- Merck Sharp & Dohme LLC
Alcohol Use Disorder, Alcohol Dependence
Altering Memories That Increase Risk of Relapse in Alcohol Use Disorders
The purpose of this study is to examine the effects of rapamycin (sirolimus) versus a placebo, an inactive substance, on responses to alcohol cues in individuals with alcohol use disorder.
- Trial name
- NCT03732248
- Testing
- Rapamycin
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Medical University of South Carolina
Viral Infection
Study to Determine the Safety, Tolerability and Pharmacokinetics of UV-4B Solution Administered Orally in Healthy Subjects
The objective is to evaluate the safety and tolerability of a single-ascending oral dose of UV-4B in healthy subjects and to determine pharmacokinetic parameters describing absorption and elimination following a single dose of…
- Trial name
- UV (NCT02061358)
- Testing
- UV-4B 3 mg, UV-4B 10 mg, UV-4B 30 mg
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
Asthma
Community Empowerment to Pilot a Novel Device for Monitoring Rescue Medication Use in Urban Children With Asthma
Background: Pediatric asthma is the most common chronic illness among children and is associated with poor quality of life, activity restriction, school absences, and thousands of physician visits annually.
- Trial name
- NCT02517047
- Testing
- CareTRx
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Boston Children's Hospital
Drug Abuse
An Explorative Pilot Study of a New Mobile Phone Application Measuring Eye Parameters of Eyes in Patients With SUD
This will be a pre-market, explorative, early feasibility, pilot, controlled clinical investigation designed to collect initial clinical data for Previct Drugs.
- Trial name
- NCT05737550
- Testing
- Previct Drugs
- Where
- Sweden
- Volunteers
- 24 people
- Sponsor
- Kontigo Care AB
Skin Diseases
Substance P Challenge in Healthy Participants
The objectives of this enabling study are to characterize the wheal and flare responses over time following skin challenges with ascending concentrations of Substance P.
- Trial name
- NCT04676763
- Testing
- Substance P, Normal Saline, Histamine
- Where
- Netherlands
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Smoking Cessation, Smoking, Tobacco
Helping Poor Smokers Quit
Using a 2x2 randomized factorial design, we will conduct a statewide field trial in Missouri to compare the relative and combined effects of these two strategies for augmenting an existing, evidence-based tobacco quitline…
- Conditions
- Smoking Cessation, Smoking, Tobacco, Smoking, Cigarette, Smoking, Pipe
- Trial name
- NCT03194958
- Testing
- Specialized Quitline, Basic Needs Navigator
- Where
- United States
- Volunteers
- 1,944 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Hepatitis C
Scale-up of Treatment of Hepatitis C Infection Among People Who Inject Drugs
This study is a phase IV, open-label, single arm, multicentre study whose aim is to assess whether interferon-free and ribavirin-free Direct Acting Antiviral (DAA) Hepatitis C Virus (HCV) therapy with grazoprevir/elbasvir, will…
- Trial name
- DARLO-C (NCT02940691)
- Testing
- Grazoprevir/elbasvir
- Where
- 5 sites in Australia
- Volunteers
- 32 people
- Sponsor
- Kirby Institute
Substance Use, Substance Use Disorders
Peer-Delivered Behavioral Activation for Methadone Adherence - Pilot Phase
The purpose of this study is to evaluate the feasibility and effectiveness of a peer-led, brief, behavioral intervention to improve adherence to medication for opioid use disorder (MOUD) among low-income, minoritized individuals…
- Conditions
- Substance Use, Substance Use Disorders, Opioid-use Disorder, Peer Delivered
- Trial name
- HEAL Together (NCT04248933)
- Testing
- Peer-Delivered Behavioral Activation (Peer Activate)
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- University of Maryland, College Park
Pulmonary Disease, Chronic Obstructive
A Study Based on Medical Records That Looks at the Duration of Use of Two Types of Inhalers With Different Medicines in Patients With Chronic Obstructive Pulmonary Disease (COPD)
To compare the persistence in using two different medications from the same drug class (LAMA/LABA FDC) which are delivered through different devices, a dry-powder inhalers (DPI) and Soft Mist Inhalers (SMI).
- Trial name
- NCT03979807
- Testing
- Olodaterol/Tiotropium Bromide, Umeclidinium/ Vilanterol
- Where
- United States
- Volunteers
- 11,296 people
- Sponsor
- Boehringer Ingelheim
Effects of Different Meals on the QT/QTc Interval, Insulin and Oral Hypoglycemic [Antidiabetic] Drugs Causing Adverse Effects in Therapeutic Use
Food and Insulin Effect on QT/QTC Interval of ECG
Moxifloxacin is routinely used as a probe to confirm assay sensitivity in thorough electrocardiogram (ECG) studies. It has been shown that a meal shortens the QT interval, which may affect pharmacokinetics (PK) and/or…
- Conditions
- Effects of Different Meals on the QT/QTc Interval, Insulin and Oral Hypoglycemic [Antidiabetic] Drugs Causing Adverse Effects in Therapeutic Use, C-Peptide Effects on the QT/QTc Interval, Moxifloxacin ECG Profile in Fed and Fasted State
- Trial name
- C11035 (NCT01642485)
- Testing
- Moxifloxacin 400 mg fasted, FDA breakfast, Continental breakfast
- Where
- United Kingdom
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Richmond Pharmacology Limited
Acute Gout
Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicine Including a 12 Weeks Extension and an Open-label 48 Weeks Extension Study
The purpose of the 12-week core study was to demonstrate that canakinumab given upon acute gout flares relieves the signs and symptoms and prevents recurrence of gout flares in patients with frequent flares of gout for whom…
- Trial name
- β-RELIEVED (NCT01029652)
- Testing
- Canakinumab 150 mg, Triamcinolone acetonide 40 mg
- Where
- 47 sites in Australia, Belgium and 15 more
- Volunteers
- 230 people
- Sponsor
- Novartis Pharmaceuticals
Substance Abuse
Preventing Drug Abuse Among Sexual Minority Youth
The planned randomized clinical trial will longitudinally test a tailored, web-based drug abuse prevention program with a nationwide sample of 15- to 17-year-old sexual minority youth (youth who identify as gay, lesbian…
- Trial name
- NCT03954535
- Testing
- Free2b
- Where
- United States
- Volunteers
- 1,216 people, healthy volunteers welcome
- Sponsor
- Columbia University
Relapsing Remitting Multiple Sclerosis
Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (MS)CombiRx
This is for a randomized clinical trial (RCT) to determine if the combined use of interferon beta-1a (IFN) and glatiramer acetate (GA) is a measurably better therapy than either agent used individually in patients with…
- Trial name
- NCT00211887
- Testing
- Interferon beta 1-a, glatiramer acetate
- Where
- 71 sites in United States, Canada
- Volunteers
- 1,008 people
- Sponsor
- Fred Lublin
Cannabis-use Disorders
Behavioral Effects of Pregabalin and Cannabis
Cannabis is the most commonly used illicit drug in the United States, and its use is associated with rates of development of abuse and dependence, treatment admission and relapse that are comparable to other illicit drugs.
- Trial name
- NCT01511640
- Testing
- Pregabalin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Joshua A. Lile, Ph.D.